Aktis Oncology (NASDAQ:AKTS) Rating Increased to Strong-Buy at Raymond James Financial

Raymond James Financial upgraded shares of Aktis Oncology (NASDAQ:AKTS) to a strong-buy rating in a report released on Monday morning,Zacks.com reports.

Several other equities analysts also recently weighed in on AKTS. William Blair began coverage on shares of Aktis Oncology in a report on Wednesday, April 29th. They issued an “outperform” rating on the stock. Weiss Ratings downgraded shares of Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a report on Tuesday, June 9th. Finally, HC Wainwright increased their price target on shares of Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $34.00.

Aktis Oncology Stock Performance

AKTS opened at $22.63 on Monday. Aktis Oncology has a 52-week low of $14.72 and a 52-week high of $29.16. The firm’s 50-day moving average is $19.40.

Aktis Oncology (NASDAQ:AKTS) last issued its quarterly earnings results on Monday, March 30th. The technology company reported ($18.17) earnings per share for the quarter. The company had revenue of $1.87 million for the quarter. On average, analysts anticipate that Aktis Oncology will post -1.62 earnings per share for the current fiscal year.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.